Aleksandra Partyńska

Ms. Aleksandra Partyńska

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2019 in Cancers
Verified
Journal Article
Open access
PDF file
KNKatarzyna Nowinska
Katarzyna Nowinska
KJKarolina Jabłońska
Karolina Jabłońska
KPKonrad Pawełczyk
Konrad Pawełczyk
APAleksandra Piotrowska
Aleksandra Piotrowska
APAleksandra Partyńska
Aleksandra Partyńska
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Background: Recent in vitro studies have indicated that irisin inhibits proliferation, migration and epithelial-mesenchymal transition. Irisin expression has not been studied in tumour tissues of non-small cell lung cancer (NSCLC) patients yet. The aim of the study was to determine the irisin expression in NSCLCs in comparison to the clinicopathological factors and expression of TTF-1, p63 and Ki-67. Material and methods: Tissue microarrays with 729 NSCLC and 140 non-malignant lung tissue (NMLT) were used to perform immunohistochemical reactions. Laser Capture Microdissection (LCM) was used to collect cancer and stromal cells from NSCLCs. FNDC5 expression was tested for LCM samples, 75 NSCLCs and 25 NMLTs with the RT-PCR technique. Western-blot, immunofluorescence reaction and RT-PCR assays were performed on lung cancer cell lines. Results: Irisin expression was observed in NSCLC cancer cells and stromal fibroblasts. In cancer cells, irisin expression was decreased in higher grades (G) of malignancy, tumour size (T) and according to lymph node metastasis. In stromal cells, irisin expression was increased in higher G and advanced T. A shorter overall survival was observed in patients with higher irisin expression in NSCLC stromal cells. Conclusions: Irisin expression in stromal fibroblasts may influence cancer cell proliferation and may be a prognostic factor for survival in NSCLC.

17 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
KJKarolina Jabłońska
Karolina Jabłońska
KNKatarzyna Nowinska
Katarzyna Nowinska
APAleksandra Piotrowska
Aleksandra Piotrowska
APAleksandra Partyńska
Aleksandra Partyńska
EKEwa Katnik
Ewa Katnik
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Background: Several studies have investigated the inhibitory effect of melatonin on lung cancer cells. There are no data available on the prognostic impact of melatonin receptors MT1 and MT2 in non-small cell lung cancer (NSCLC). Materials and Methods: Immunohistochemical studies of MT1 and MT2 were conducted on NSCLC (N = 786) and non-malignant lung tissue (NMLT) (N = 120) using tissue microarrays. Molecular studies were performed on frozen fragments of NSCLC (N = 62; real time PCR), NMLT (N = 24) and lung cancer cell lines NCI-H1703, A549 and IMR-90 (real time PCR, western blot). Results: The expression of both receptors was higher in NSCLC than in NMLT. Higher MT1 and MT2 expression levels (at protein and mRNA) were noted in squamous cell carcinomas (SCC) compared to adenocarcinomas (AC). MT1 immunoexpression decreased as both the tumour size and the cancer stage increased in the whole cohort, while MT2 decreased as the cancer stage increased, with lymph node involvement (in the whole study group) and increasing malignancy grade (in SCC). Higher expression of MT2 was associated with a favorable prognosis. MT2 was an independent prognostic factor for overall survival (OS) in all analyzed NSCLC and in smoking patients. Conclusions: Our observations may point to the potential prognostic significance of MT2 in NSCLC.

15 May 2019 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KNKatarzyna Nowinska
Katarzyna Nowinska
UCUrszula Ciesielska
Urszula Ciesielska
APAleksandra Piotrowska
Aleksandra Piotrowska
KJKarolina Jabłońska
Karolina Jabłońska
APAleksandra Partyńska
Aleksandra Partyńska
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Background/Aim: The minichromosome maintenance proteins (MCMs) may be potential biomarkers of cancer cell proliferation. They are essential to initiate DNA replication. The aim of the study was to investigate the level of MCM5 expression in benign lesions (BLs) and laryngeal squamous cell cancer (LSCC). Materials and Methods: Immunohistochemical (IHC) analysis was carried out on 83 LSCCs and 10 BLs. Western-blot, immunofluorescence analysis (IF) and real-time PCR (RT-PCR) were performed using HEp-2 cancer cells and HaCaT keratinocytes. Results: The expression of MCM5 was higher in LSCC than in the BLs (p<0.0001) and was higher in subsequent malignancies of LSCC. Positive correlations were demonstrated between the expression levels of MCM5 and the Ki-67 antigen. In vitro studies have confirmed that the expression of MCM5 is elevated in cancer cells. Conclusion: MCM5 protein may be used as a potential marker of cancer cell proliferation in LSCC.

27 October 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
APAleksandra Partyńska
Aleksandra Partyńska
AGAgnieszka Gomulkiewicz
Agnieszka Gomulkiewicz
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
MPMarzenna Podhorska-Okolow
Marzenna Podhorska-Okolow
Zyxin (ZYX) is a LIM domain protein whose presence has been detected in the cytoplasm and nucleus. ZYX can translocate between these two compartments and therefore, can take part in the regulation of various cellular processes. VASP and α-actinin are examples of proteins that interact with ZYX. As ZYX is present in focal adhesions (FAs), an immense part of research is focused on the role of this protein in the organisation and function of the cytoskeleton. Other studies aim to explain the impact of zyxin on other intracellular processes. Zyxin has been shown to take part in apoptosis, as well as in wound healing. Additionally, zyxin contribution to cancer development is gaining growing interest. This paper aims to systematise the knowledge on zyxin and its role in carcinogenesis.

7 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
HJHanna Jankowska-Ziemak
Hanna Jankowska-Ziemak
MKMagdalena Kulus
Magdalena Kulus
APAleksandra Partyńska
Aleksandra Partyńska
JKJakub Kulus
Jakub Kulus
KDKrzysztof Piotr Data
Krzysztof Piotr Data
Bartosz KempistyBartosz Kempisty
Bartosz Kempisty
Angiogenesis, the formation of new blood vessels from existing vasculature, is regulated by a balance between pro- and anti-angiogenic factors. In adults, this process typically occurs in response to inflammation, wound healing, and neoplastic growth. Uniquely, the female reproductive system undergoes cyclical and repetitive angiogenesis with folliculogenesis, decidualization, implantation, and embryo development throughout the reproductive cycle. Ovarian angiogenesis involves a coordinated network of signaling pathways and molecular factors. Vascular endothelial growth factor (VEGF) is the primary driver of this process, supported by other regulators such as fibroblast growth factor (FGF) and hypoxia-inducible factor (HIF). Understanding the molecular mechanisms that govern ovarian angiogenesis is essential for developing new diagnostic and therapeutic approaches in reproductive medicine. Vascular dysfunction and impaired angiogenesis are key contributors to various ovarian disorders and infertility, including polycystic ovary syndrome (PCOS). Therefore, in-depth studies of ovarian vascularization are crucial for identifying the pathophysiology of these conditions and guiding the development of effective treatments. Advancing knowledge in this area holds significant potential for innovation in both medicine and biotechnology.

1 December 2022 in Anticancer Research
Verified
Journal Article
Open access
PDF file
APAleksandra Partyńska
Aleksandra Partyńska
APAleksandra Piotrowska
Aleksandra Piotrowska
KPKonrad Pawelczyk
Konrad Pawelczyk
ARAdam Rzechonek
Adam Rzechonek
KRKatarzyna Ratajczak-Wielgomas
Katarzyna Ratajczak-Wielgomas
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Background/Aim: KAT6A is considered a factor influencing carcinogenesis. Due to the fact that lung cancer is one of the leading causes of death, the aim of our study was to evaluate KAT6A expression in non-small cell lung cancer (NSCLC) tumors and the NSCLC cell line model. Materials and Methods: The expression of KAT6A was examined in NSCLC tumors by real-time PCR and immunohistochemistry. KAT6A expression was investigated in the NSCLC cell line model by real-time PCR, western blot, and immunofluorescence. Results: KAT6A protein level was elevated in NSCLC tumors compared to non-malignant lung tissues (NMLT). The KAT6A mRNA expression in NSCLC, lung adenocarcinoma, and lung squamous cell carcinoma samples was differentiated. The results from the in vitro NSCLC model demonstrated elevated expression of KAT6A in lung cancer cell lines in comparison to normal lung fibroblasts. Conclusion: The outcomes showed an increased KAT6A protein level in NSCLC compared to control samples, which suggests the oncogenic role of KAT6A in this type of cancer. Therefore, targeting KAT6A in NSCLC might be worth consideration.